Glioblastoma vs temozolomide: can the red queen race be won?
| Autor: | Anjali Arora, Kumaravel Somasundaram |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty DNA Repair Combination therapy medicine.medical_treatment Brain tumor Review 03 medical and health sciences Race (biology) 0302 clinical medicine Internal medicine Glioma Antineoplastic Combined Chemotherapy Protocols Temozolomide medicine Humans Antineoplastic Agents Alkylating Microbiology & Cell Biology Pharmacology Clinical Trials as Topic Chemotherapy business.industry Mechanism (biology) medicine.disease Combined Modality Therapy Treatment Outcome 030104 developmental biology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Molecular Medicine Glioblastoma business medicine.drug |
| Zdroj: | Cancer Biol Ther |
| ISSN: | 1555-8576 1538-4047 |
| Popis: | Glioblastoma is the most invasive form of brain tumor. Although temozolomide chemotherapy has been shown to significantly improve survival in patients with GBM, this increase is only trivial. The underlying cause is that many GBMs do not respond to temozolomide, and the rest produces resistance. In the past two decades, many attempts have been made to understand resistance mechanisms and to combine other treatments with temozolomide to maximize patient benefit. Unfortunately, it seems to be a red queen game, and the speed of disease development is as fast as the progress in the field. In order to win this game, a comprehensive approach is needed to decipher the details of the resistance mechanism and to transfer the basic research to the clinic. This article reviews the following: temozolomide discovery, chemistry, and mechanism of action, and mechanisms of resistance, as well as combination therapy with other strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|